



October 24, 2021

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards the Company having achieved a significant milestone by setting a new GUINNESS WORLD RECORDS™ title for creating the Largest book sentence.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOR LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal,
2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29
a5f00491762a5ac549cb034cae, postalCode=400104,
st=Maharashtra,
serialNumber=df8ebe60a88c796663c738ea25bfa0b475
d195f726cdb67a2ff09c4242771b2a, cn=Rajvardhan
Vishnu Satam
Date: 2021.10.24 13:02:02 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS -1 1973)**

Encl- : a/a.

Lupin makes a hearty entry into Guinness World Records Creates awareness on monitoring heart rate as an indicator of overall health

Mumbai, India, October 24, 2021: Global pharma major Lupin Limited (Lupin) has achieved a significant milestone by setting a new GUINNESS WORLD RECORDS™ title for creating the **Largest book sentence**. The title was developed with 5000 book copies to display the letters in the sentence '**Heart Rate, Is it a Missing Link?**' (title of the book). This unique record was made possible by collating hard copies of the books in a structured manner under the supervision of an official from Guinness World Records, London.

According to the World Health Organization (WHO), India accounts for one-fifth of the total deaths occurring from stroke and ischemic heart disease. An upward trend of an arrhythmic heart rate signals a larger health problem in most individuals. To draw attention to this critical health parameter, Lupin attempted this record to talk about preventive care and treatment strategies for patients with an elevated heart rate. The record was monitored by an adjudicator from Guinness World Records.

Speaking on the occasion, Rajeev Sibal, President – India Region Formulation, Lupin Limited said, "We are delighted to set a Guinness World Records title which will help in raising awareness on Heart rate and its connection to well-being. Blood Pressure and sugar monitoring are prevalent the world over, however heart rate tracking needed to be one of the critical health indices as a measure of good health. Our endeavour was to bring this aspect to the fore amongst the medical fraternity and for this book to serve as a ready reckoner in India and overseas. We are thankful to our eminent cardiologists who participated in the making of this book and curating this event."

The book has been conceptualized and authored by eight eminent practicing Cardiologists, including Dr. J. C. Mohan, Dr. Monotosh Panja, Dr. I. Sathyamurthy, Dr. Rajeev Agarwala, Dr. Brian Pinto, Dr. C.K. Ponde, Dr. A. Sreenivas Kumar and Dr. B. K. Mahala, after multiple rounds of detailed deliberations with 500+ doctors from across the country. It interlinks elevated heart rate and the onset various heart disease manifestations. The 5,000 books that were part of the record-breaking event will be distributed to heart specialists and medical practitioners across the country.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com